Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism.

Biancur DE, Paulo JA, Małachowska B, Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, Harper JW, Fendler W, Mancias JD, Kimmelman AC. · 2017

Read Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. by Biancur DE, Paulo JA, Małachowska B, Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, Harper JW, Fendler W, Mancias JD, Kimmelman AC. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5500878.txt.

Description

Biancur and co-authors report a cancer metabolism study in Nature Communications. Pancreatic ductal adenocarcinoma is hard to treat and often deadly. These tumors lean heavily on glutamine, an amino acid, for growth. Blocking an early glutamine enzyme, GLS, looked like a sound drug plan. The team tested a potent GLS blocker called CB-839.

The drug slowed pancreatic cancer cells strongly at first, they report. The cells then adapted and kept growing, in dishes and in mice. Protein and metabolite profiling revealed the backup routes they used. Pairing the blocker with drugs against those routes worked better. The authors argue that such rational pairs may help patients.

Catalog record

CREATORBiancur DE, Paulo JA, Małachowska B, Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, Harper JW, Fendler W, Mancias JD, Kimmelman AC.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5500878

Browse the full library · About the Tower of Babel